Clinical Trial Update: CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a CD33-targeted CAR T cell therapy for recurrent or refractory acute myeloid leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD33-CAR T cell therapy

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING